A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation

Transfusion

Volumn 51, Issue 8, 2011, Pages 1779-1783

  Renfroe, Heather ^a,b   Arnold, Mike ^a,b   Vaughn, Louette ^a,b   Harvey, R Donald ^a,b   Hamilton, Ellie ^a,b   Lonial, Sagar ^a,b   Khoury, H Jean ^a,b   Kaufman, Jonathan L ^a,b   Lechowicz, Mary Jo ^a,b   Flowers, Christopher R ^a,b   Waller, Edmund K ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMEN; ADIPOSE TISSUE; ADULT; AGED; APHERESIS; ARM; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY MASS; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; HODGKIN DISEASE; HUMAN; INJECTION SITE; LEG; LYMPHOCYTE COUNT; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; DRUG ADMINISTRATION ROUTES; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 80051660813     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.03052.x     Document Type: Article

References (14)

1. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD,. Granulocyte-macrophage colony stimulating factor expands the circulating hematopoietic progenitor cell compartment in man. Lancet 1988; 28: 1194-8.
2. Nowrousian MR, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P, Flasshove M, Moritz T, Schuette J, Seeber S,. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol 2003; 14: i29-36. (Pubitemid 36701721)
3. Cassens U, Momkvist PH, Zuehlsdorf M, Mohr M, Kienast J, Berdel WE, Sibrowski W,. Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC). Bone Marrow Transplant 2001; 28: 13-20. (Pubitemid 32707612)
4. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Wasman A, Yahalom J, Moskowitz CH,. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-8. (Pubitemid 38596282)
5. Sola C, Maroto P, Salazar R, Mesia R, Mendoza L, Brunet J, Lopez-Pousa A, Tabernero JM, Montesinos J, Pericay C, Martinez C, Cancelas JA, Lopez-Lopez JJ,. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): the CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999; 4: 195-209. (Pubitemid 30011407)
6. Toor AA, Ayers J, Strupeck J, Parthasarathy M, Creech S, Rodriquez T, Stiff PJ,. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol 2004; 124: 769-76. (Pubitemid 38365782)
7. Gazitt Y, Freytes CO, Callander N, Tsai TW, Alsina M, Anderson J, Holle L, Cruz J, Devore P, McGrath M, West G, Alvarez R, Montgomery W,. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization. J Hematother 1999; 8: 172-83.
8. DiPersio JF, Smith A, Sempek D, Baker A, Jiang S, Vij P, Cashen A, Westervelt P,. Kinetics of autologous stem cell mobilization failure: comparison of AMD3100/G-CSF, G-CSF, GM-/G-CSF, and chemotherapy/G-CSF on remobilization success. ASH Annual Meeting Abstracts 2006; 108: 3380.
9. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM, Markovic SN,. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantaion in multiple myeloma or non-Hodgkin's lymphoma. Blood 2001; 98: 579-85.
10. Blystad AK, Delabie J, Kvaloy S, Holte H, Valerhaugen H, Ikonomou I, Kvalheim G,. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004; 125: 605-12. (Pubitemid 38747963)
11. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL,. Factors influencing the absorption, serum insulin concentration, and blood glucose reponses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981; 4: 366-76. (Pubitemid 12201586)
12. Beshyah SA, Anyaoku V, Niththyananthan R, Sharp P, Johnston DG,. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clin Endocrinol (Oxf) 1991; 35: 409-12.
13. Teshima T, Harada M, Takamatsu Y, Makino K, Taniguchi S, Inaba S, Kondo S, Tanaka T, Akashi K, Minamishima I,. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 1992; 10: 215-20.
14. Hicks ML, Lonial S, Langston A, Flowers C, Roback JD, Smith KJ, Mossavi Sai S, Teagarden D, Hamilton ES, Kaufman J, Waller EK,. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion 2007; 47: 629-35. (Pubitemid 46449623)